Evidence-based articles on Wegovy, Zepbound, Mounjaro, Ozempic, BMI, BMR, and online telehealth programs. Written to help you lose weight safely.
Answer 5 quick questions to get your personalized weight loss projection with GLP-1 medication.
We'll use this to calculate your personalized weight loss projection.
Post-bariatric weight regain affects up to 50% of patients — and GLP-1s are becoming the standard treatment. Safety, effectiveness, and the dumping syndrome question.
GLP-1s aren't approved for type 1 diabetes — but some T1D patients use them off-label. The evidence, the DKA risk, and what endocrinologists say.
Sleeve gastrectomy patients regain too — and GLP-1s are the standard medical response. Safety on sleeved anatomy, effectiveness, and the protocol.
Bipolar patients gain weight from mood stabilizers — and GLP-1s could help. The interaction picture, mood monitoring, and what psychiatrists consider.
Crohn's patients face a specific GLP-1 question: how do GI side effects land on an already-inflamed gut? The safety picture and monitoring protocol.
The old-school appetite suppressant vs the new standard. Effectiveness, safety, cost, and whether combining them makes sense.
Your GLP-1 was working — then it stopped. Why plateaus happen, how long they last, and the 7 fixes that actually break through.
Older adults lose weight on GLP-1 too — but muscle loss and frailty change the calculus. The senior-specific risks and the protocol that protects them.
Wegovy is FDA-approved for adolescents 12+ — and the debate is real. The evidence, the growth and eating disorder concerns, and what parents should know.
Brides and grooms are starting GLP-1 for the wedding — here's the realistic timeline, the dress fitting strategy, and the mistakes that ruin the plan.
Stopping GLP-1 cold turkey usually means regain — but does tapering help? The evidence, the schedules, and who can actually get off successfully.
Anthem (Elevance Health) covers GLP-1s on many commercial plans with PA — but employer exclusions are common. Formulary status, criteria, and alternatives.